Pharmaceutical Bio Association Publishes 'Global Issue Panorama' Analyzing Industry Issues

Global Issue Report Published Occasionally
"Understanding Global Status and Seeking Response Strategies"

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on the 21st that it has published the first issue of the report "Global Issue Panorama," which investigates and analyzes major issues such as domestic and international pharmaceutical and bio policies and systems.

Korea Pharmaceutical and Bio-Pharma Manufacturers Association building. [Photo by Korea Pharmaceutical and Bio-Pharma Manufacturers Association]

Global Issue Panorama was created with the purpose of helping establish optimal strategies with a broad perspective on the industry by analyzing key issues in pharmaceuticals and bio-pharma. Panorama refers to a photographic technique that captures scenery from multiple directions at once when shooting a wide landscape.

The inaugural issue of Global Issue Panorama focused on the main theme "Post-Pandemic, Domestic COVID-19 Vaccine Research and Development Must Continue." It emphasized the need for the domestic vaccine industry’s prompt response and continued government support in relation to the U.S. Food and Drug Administration (FDA)’s annual COVID-19 vaccine administration and simplification of vaccine composition. The report also included the association’s survey results on the domestic vaccine industry, which identified the biggest challenge in vaccine R&D as a lack of funding, followed by shortages of personnel and infrastructure.

Additionally, it covered major global developments such as ▲ the World Health Organization (WHO) initiating negotiations on a global agreement to prepare for future pandemic emergencies ▲ the European Union (EU) planning to apply regulatory sandboxes for new drug development and evaluation. The association’s Education and Research Center plans to continuously analyze and publish various topics related to the industry, including ▲ global pharmaceutical and bio-related policies (regulations) ▲ domestic and international market and research and development (R&D) status.

An association official stated, "For the domestic pharmaceutical and bio industry to achieve global competitiveness, it is important to move forward based on an accurate diagnosis of current issues," adding, "We will provide analyses from internal and external experts and work with the industry to consider directions for sustainable growth."

This content was produced with the assistance of AI translation services.